my country's first anti -new crown oral medicine is here!Azf's fixed tablet for the treatment of new coronary pneumonia indications registered phase III clinical trials The main efficacy indicators reached expected

Henan Daily Client reporter Ke Yang Li Xiaomin

Azfdin, who has been approved for more than two years of phase III clinical trials, is expected to become my country's first oral anti -new crown drug with completely independent intellectual property rights!

On July 15th, Henan Real Biotechnology Co., Ltd. (hereinafter referred to as "real creature") announced that it has officially submitted a listing application for the treatment of new coronary virus indications to the National Drug Administration for the treatment of new coronary virus.

Since April 2020, Azf has been approved at home and abroad to conduct phase III clinical trials. The clinical trial results show:

(1) Significant improvement of clinical symptoms: Azf's fixed tablet can significantly shorten the moderate new type of coronary virus infection with pneumonia patients, improve the proportion of patients with improvement of clinical symptoms, and achieve clinical excellent results. On the first 7th day of the administration, the proportion of the subjects of the clinical symptoms improved 40.43%, and the placebo group was 10.87%(P value <0.001). There are very significant statistical differences with the placebo group (P value <0.001).

(2) Inhibit the role of new coronal virus: Azf will definitely have the activity of inhibiting the new coronary virus, and the virus clearance time is about 5 days.

(3) In terms of safety: The overall tolerance of Azf's fixed decision is good, and the incidence of adverse events has no statistical differences with the placebo group, and the risk of the subject does not increase.

It is understood that Azf is the world's first double -target anti -AIDS innovation medicine, and has applied for patents in many countries such as China, the United States and other countries. As a antivirus small molecule oral medication, Azf has a broad -spectrum to inhibit the replication of RNA virus, while the new coronal virus belongs to RNA as a hereditary virus, so the medicine has inhibitory effects on the new crown virus.

Dr. Du Jinfa, the chief scientist of the real biology, said: "We are very happy to usher in this important moment. I look forward to Azf's early approval and provide a force for the prevention and control of domestic and global epidemic conditions."

Azf's Drug Inventor, former president of Henan Normal University, now said: "We break through traditional ideas, develop new strategies for nucleoside drug design, and innovate the process of using virus replication. The characteristics of the China Micro -Environment RNA polymerase make the drug activate and play a role in situ in place in the target cell. In addition, further research has proved that the half -life of Azf in CD4T cells is greater than 120 hours, and its drug target target Strong orientation and long -term. "

Jiang Jiandong, an academician of the Chinese Academy of Engineering and the dean of the Beijing Academy of Pharmaceutical Research, Chinese Academy of Medical Sciences, said: "Azf has obvious anti -new coronal virus effects, which is effective for patients with clinical enlightening. The new crown of mechanism, this is its distinctive biological characteristics. "

- END -